Return to Clinical Trials Search Results

A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer

Primary Objectives: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. Secondary Objectives: To assess the preliminary anti-tumor activity of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. To determine the pharmacokinetic profile of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. To determine the pharmacodynamics (biomarkers) of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced solid tumors.

Primary Objectives: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. Secondary Objectives: To assess the preliminary anti-tumor activity of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. To determine the pharmacokinetic profile of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. To determine the pharmacodynamics (biomarkers) of BBI503 when administered in combination with selected anti-cancer therapeutics in adult patients with advanced solid tumors.